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Every dermatology consultation - think adherence 
 
 ǲWhat would you like to help you daily treat your skin? We can offer a regular 
text reminder, or arrange a friend of yours to encourage you on Facebook, or you 
could join our free Treatment Treats scheme (you earn ten points each time you 
put the treatment on!).  Or, right now, you could go for a five minute Treatment 
Success tutorial with our specialist nurse to discuss the best ways to squeeze your treatment into your hectic life.ǳCrazy ideas? Maybe, but somehow clinicians 
need to wake up to the invisible sea of non-adherence that they are floating in.   
 
About 95% of dermatology patients under-dose when using new topical 
therapies1 and 30% didn’t even pick up their outpatient prescription drugs2.   
There are even problems with adherence for inpatients despite direct 
supervision by the care team3. In acne, there is an overall risk of poor adherence 
of 50%4.  Why does non-adherence matter? Because lack of use of prescribed 
therapies results in lack of effectiveness, with resulting prolongation of time to 
improvement or cure and wasted clinic appointments. Furthermore, there is 
dissipation of scarce resources and clinicians get an inaccurate understanding of 
the appropriateness and effectiveness of the advice they gave. 
 
In this issue, Alinia et al5 examine long term adherence to topical medication and 
demonstrate that it is ǲabysmalǳ.  Their’s is a critical exposé, striking at the heart 
of one of the main tenets of clinical practice.  They used a Review Board-
approved technique of using ointment medication containers with hidden 
electronic monitoring, and were able to follow-up 20 patients for a full 12 
months.  Even in the first month, no medication was used on 37% of days; by 
month 12, none was used on 51% days.  Patients in an intervention comparison 
group were asked to report weekly on the state of their disease: interestingly, 
even this modest patient engagement technique was associated with improved 
adherence. 
 
What does any of this have to do with the practice of dermatology around the 
world? Firstly, we must recognise that patients often don’t use therapy in the 
way that we advise.  Secondly, although tempting to think that we improve this 
with a mixture of persuasion, encouragement and warnings, we need to open our 
minds to understanding poor compliance.  Thorneloe et al6 have shown that the 
reasons behind non-adherence are complicated and subtle.  Their detailed 
interviews with 20 patients with psoriasis revealed the reality, and often 
impossibility, of trying to integrate regular therapy with their daily lives.  Daily 
treatment adds extra distress, and non-adherence may be a deliberate way for a 
patient to try to regain some personal control.  Unless you understand a patient’s 
mood and beliefs, your strategy for improving adherence will probably fail.   
 
Erntoft et al7 recently gave another insight into non-adherence, in treatment of 
actinic keratoses. Using a strict definition of adherence, they showed a more 
encouraging level of adherence, with 75% adherent to both recalled frequency and regularity of topical treatment. They identified a group of ǲover-persistentǳ 
patients who stayed on treatment longer than suggested, presumably because 
they were so keen to get some therapy benefit, or maybe they wanted to give the 
therapy maximum chance of working before abandoning it. So poor adherence doesn’t only mean too little therapy. 
 
Thus, we have good evidence that many of our patients don’t apply their topical 
preparations as advised and that some don’t even get their medications from the 
pharmacy. Recognising this, why are clinicians apparently unaware of this 
problem?  Are the detailed realities of life of our patients, as revealed by the Thornloe et al’s powerful patient quotes6, beyond our understanding? If not, how 
can we clinicians hope to better understand the complexities and barriers to 
good compliance in our patients? 
 
It would be helpful clinically if adherence could be easily measured.  The 
problem, let’s be frank, is that patients do not always accurately report their therapy usage (they’re often ǲeconomical with the truthǳ8).  There is 
considerable experience of this from clinical trials where even self-completed 
diary entries are sometimes falsified.  That’s why in the research context the 
techniquedescribed in this issue by Alinia et al5of covert electronic monitoring of 
therapy treatment containers is exciting.  It is possible to imagine that the use of 
such electronic devices could be used overtly to assist patient adherence.  But is 
there any way now that you can recognise who is likely to be a poor adherer?  
We suggested that, at follow-up, asking the simple non-threatening question ǲ What treatment did you use yesterdayǳ might alert one to a problem of 
adherence and anyway open up the subject for discussion9: but there is no actual 
evidence for this.  In psoriasis, younger, male patients with early onset of 
psoriasis and high self-assessed severity of psoriasis experienced adherence 
issues10, but it is probably better to assume at first with all patients that 
adherence may need to be supported, until proven otherwise. 
 
What can be done to make regular treatment easier for patients and to motivate 
them to actually use their drugs? When using systemic drugs, the prescribed 
number of doses per day is inversely related to compliance11.  It therefore makes 
sense to also prescribe topical therapy on a once-only daily basis, if there is a 
choice.  The physician-patient relationship is a primary determinant of 
adherence12. Understanding and acting on patient preference, providing 
appropriate patient education and adjusting the treatment regimen to suit the 
individual are all important12. 
 
Finally, there is a mostly unexploited resource available that could make a huge 
difference to adherence: the ǲGreater Patientǳ13.  Skin disease doesn’t only affect 
the life of the patient, it can also have a major impact on the quality of life of the patient’s close relatives or partner13,14.  There is often at least one person close to the patient who would gain if the patient’s condition improved; that person is 
likely to be easily motivated to assist good treatment adherence.  If a close relative could be encouraged to take on this role (of course with the patient’s 
permission and support), then the ǲGreater Patientǳ team could be jointly 
educated with targeted adherence discussion and advice.  Joint family education 
programmes have been effective in the management of childhood eczema and 
this concept could be built upon for other skin diseases. 
 
So after reading this, at your next clinic, and at every consultation try thinking about adherence.  You’ll be an even more effective clinician. 
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